Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
November 29, 2024 1:48 AM 2 min read

Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments

by Kaustubh Bagalkote Benzinga Staff Writer
Follow
FlipboardIcon version of the Flipboard logo

Cathie Wood, founder and CEO of ARK Investment Management LLC, defended the future of artificial intelligence investments while highlighting Tesla Inc. (NASDAQ:TSLA) as a cornerstone of technological innovation during a recent podcast appearance with SoFi‘s Head of Investment Strategy, Liz Thomas.

What Happened: Wood popularly known for leading ARK Innovation ETF (NYSE:ARKK) characterized Tesla as “the largest AI project on Earth,” emphasizing AI’s transformative potential across multiple sectors.

She particularly highlighted healthcare advancements, where AI’s convergence with sequencing technologies could revolutionize cancer diagnosis through blood testing, especially when combined with CRISPR gene editing capabilities.

Addressing concerns about heavy GPU and cloud infrastructure investments by major tech companies, Wood acknowledged investor skepticism about capital expenditure increases.

Wood cited Microsoft Corp‘s (NASDAQ:MSFT) dramatic spending surge from $30 billion to $60 billion in 18 months as an example of investments that have yet to demonstrate clear returns.

See Also: Bitcoin, Ethereum, Dogecoin Simmer Down On Thanksgiving: Analyst Sees ‘Significant Shift’ From BTC Season To Alt Season

Wood’s investment thesis extends beyond Tesla to the broader biologics sector, where she envisions a $400 billion market opportunity emerging from the convergence of AI, genetic sequencing, and gene editing technologies.

Read Next:

  • Meta, TikTok, Snapchat Could Face $32M Fines As Australia Enforces Social Media Ban For Under-16s

Image via Ark Invest

Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
EquitiesNewsGlobalMarketsartificial intelligenceCathie WoodKaustubh Bagalkote
ARKG Logo
ARKGARK Genomic Revolution ETF
Not Available-%
Overview
ARKK Logo
ARKKARK Innovation ETF
$73.57-0.97%
CRSP Logo
CRSPCRISPR Therapeutics AG
$58.51-0.46%
MSFT Logo
MSFTMicrosoft Corp
$407.88-0.37%
TSLA Logo
TSLATesla Inc
$396.80-0.47%
TWST Logo
TWSTTwist Bioscience Corp
$48.33-%

Why It Matters: The ARK Invest CEO’s comments come amid her firm’s recent portfolio adjustments, including an $18 million reduction in Tesla holdings through its flagship funds. Despite these sales, Wood maintains a bullish long-term outlook on Tesla’s autonomous driving potential, projecting a “trillion-dollar-plus revenue opportunity.”

Her ARK Genomic Revolution ETF (BATS:ARKG), managing $1.179 billion in assets, reflects this conviction through significant investments in companies like Twist Bioscience Corp. (NASDAQ:TWST) and CRISPR Therapeutics AG (NASDAQ:CRSP).

Responding to concerns about elevated market valuations, Wood noted that current market multiples in the low 20s leave little room for error. However, she remains confident in the emergence of transformational business models, particularly at the intersection of AI and healthcare innovation, where she sees potential for revolutionary advances in disease treatment and diagnosis.

ARKG Logo
ARKGARK Genomic Revolution ETF
Not Available-%
Overview
ARKK Logo
ARKKARK Innovation ETF
$73.57-0.97%
CRSP Logo
CRSPCRISPR Therapeutics AG
$58.51-0.46%
MSFT Logo
MSFTMicrosoft Corp
$407.88-0.37%
TSLA Logo
TSLATesla Inc
$396.80-0.47%
TWST Logo
TWSTTwist Bioscience Corp
$48.33-%
Comments
Loading...